69008 Lyon, France

Jean-Jacques Berthelon

This inventor holds 1 USPTO granted patent. Active years: 1995.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Jacques Berthelon. Retrieved from https://idiyas.com/inventor/jean-jacques-berthelon-ji8sw4f7

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Years Active: 1995

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jean-Jacques Berthelon: Innovator in Immunomodulatory Compounds

Introduction

Jean-Jacques Berthelon is a notable inventor based in Lyon, France. He has made significant contributions to the field of immunomodulatory compounds, particularly through his innovative research and patent work.

Latest Patents

Berthelon holds a patent for "Substituted flavonoid compounds, their salts, their manufacture and the use of substituted flavonoid compounds which have the immunomodulatory activity." This patent highlights the potential of these compounds in boosting natural killer activity in vivo and inducing interferon, particularly in the context of cancer therapy. His work focuses on flavonoids of a specific formula, showcasing their therapeutic applications.

Career Highlights

Throughout his career, Berthelon has demonstrated a commitment to advancing scientific knowledge in his field. His research has led to the development of novel compounds that may play a crucial role in cancer treatment.

Collaborations

Berthelon has collaborated with esteemed colleagues such as Phillipe Briet and Francois Collonges. These partnerships have enriched his research and contributed to the advancement of immunomodulatory therapies.

Conclusion

Jean-Jacques Berthelon's work exemplifies the intersection of innovation and healthcare, particularly in the development of compounds that may enhance cancer therapies. His contributions continue to influence the field of immunology and cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…